{
    "2021-10-29": [
        [
            {
                "time": "",
                "original_text": "【公告速读】十月第四周医药重点公司重要公告",
                "features": {
                    "keywords": [
                        "公告",
                        "医药",
                        "重点公司"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "医药资本大佬被证监会立案调查，曾忽悠复星",
                "features": {
                    "keywords": [
                        "医药",
                        "资本",
                        "证监会",
                        "立案调查",
                        "复星"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "瑞信：维持复星医药(2196.HK)跑赢大市评级 目标价下调至51港元 机构下调估值",
                "features": {
                    "keywords": [
                        "瑞信",
                        "复星医药",
                        "跑赢大市",
                        "目标价下调",
                        "机构下调估值"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "斥巨资投资后，有药企开始出现“消化不良”",
                "features": {
                    "keywords": [
                        "巨资投资",
                        "药企",
                        "消化不良"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "复星医药(600196)：业绩持续稳健增长 创新管线丰富布局",
                "features": {
                    "keywords": [
                        "复星医药",
                        "业绩增长",
                        "创新管线",
                        "丰富布局"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}